莎普爱思: 莎普爱思关于获得硫酸特布他林雾化吸入用溶液《药品注册证书》的公告

Group 1 - The company has received the Drug Registration Certificate for Sulbutamol Nebulization Solution, which is classified as a chemical drug of category 4 [1][2] - The drug is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1] - The total R&D investment for this drug has reached approximately 5.0111 million RMB [2] Group 2 - The approval of the drug will enrich the company's product portfolio and optimize its product layout [2] - Future production and sales of the drug are subject to uncertainties due to factors such as pharmaceutical industry policies, bidding procurement, and market environment changes [2]